Scholars Central

Conference abstractPublished 29 Oct 2012

Discovery of potent, selective and efficacious p38 MAPK inhibitor as clinical drug candidate

Authors: Li Xing

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

PH-797804 is a diarylpyridinone inhibitor of p38α mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS). Based on structural analysis of dozens of high resolution crystal structures of p38α inhibitor complexes, PH-797804 is predicted to possess high level of specificity across the broad human kinase genome. We used a structural bioinformatics approach to identify two selectivity elements encoded by the TXXXG sequence motif on p38α kinase hinge. Kinome-wide sequence mining revealed rare presentation of the selectivity motif. Corroboratively, PH-797804 exhibited exceptionally high specificity against MAP kinases and the related kinases. No cross-reactivity was observed in large panels of kinase screens (selectivity ratio >500 fold). In cellular assays PH-797804 demonstrated superior potency and selectivity consistent with the biochemical measurements. Efficacy was achieved in animal models and certain human disease population. The compound is well-tolerated in phase I clinical trials, and is under phase II development for the treatment of several inflammatory diseases.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Drug Designing: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Li Xing”